Biogen

TYSABRI

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Biogen

Tysabri HCPCS:

J2323

HCPCS Code Descriptor:

Injection, natalizumab, 1 mg

Category:

J Code

Tysabri NDCs:

64406-0008-01

Primary Type:

Neurology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Tysabri CPT Codes:

Potential CPT administration codes for Tysabri can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Tysabri:

TYSABRI is a Neurology drug manufactured by Biogen and administered via the Intravenous route of administration. The J Code: J2323 is aligned to the drug TYSABRI.

TYSABRI is an integrin receptor antagonist used to treat Crohn’s Disease (CD) and Multiple Sclerosis (MS). TYSABRI (J2323) is indicated as a monotherapy for relapsing MS. It acts by binding the ɑ4 subunit of two integrins in the ɑ4 integrin family that are expressed by all leukocytes except for neutrophils. This prevents vascular cell adhesion molecule-1 and mucosal addressing cell adhesion molecule-1 from binding the integrins, keeping the leukocytes from moving across endothelium into inflamed parenchyma and preventing further inflammation. Patient assistance for this medication can be found through Biogen.

ACCESS PRICING AND MORE BY REGISTERING

J2323 Added Date:

January 1, 2008

J2323 Effective Date:

January 1, 2008

J2323 Termination Date:

HCPCS Active

Tysabri billing and coding information can be found through Biogen at the link below:
Tysabri patient assistance information can be found through Biogen at the URL: https://www.biogen.com/en_us/financial-assistance.html
TYSABRI prescribing information can be found at the link below:
Information regarding TYSABRI’s side effects can be found at MedlinePlus